Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | PIN4 | Q9Y237 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311885 | 0.85 | CYP11B1 (0.48) | ALDH1A1RAB9ASMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL2531890 | 0.79 | CYP11B1 (0.52) | ALDH1A1RAB9ASMN1; SMN2TBXAS1KMT2A | |
| Hydrochloric Acid SCHEMBL25311465 | 0.78 | CYP11B1 (0.38) | ALDH1A1PTGS2KMT2AMEN1MAPT | |
| SCHEMBL18838185 | 0.76 | RAB9A (0.48) | ALDH1A1RAB9ASMN1; SMN2GSK3AGSK3B | |
| SCHEMBL27831350 | 0.75 | ALDH1A1 (0.70) | ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27811680 | 0.73 | ADORA2B (0.44) | ALDH1A1MAPK1KMT2AMEN1HSD17B10 | |
| SCHEMBL27482241 | 0.72 | TBXAS1 (0.50) | TBXAS1 | |
| SCHEMBL10233671 | 0.70 | — | — | |
| SCHEMBL10036618 | 0.70 | KCNH2 (0.34) | — | |
| SCHEMBL6776094 | 0.70 | CYP11B1 (0.62) | ALDH1A1MAPTTSHRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2273980-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2225252-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | Novartis AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009068567-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068567-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | INPP5B, PPIP5K2, INPPL1 | ALDH1A1 4630/4885RAB9A 198/4885SMN1; SMN2 731/4885 |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | SOST, SLC20A1, SLC34A1 | ALDH1A1 3443/4885RAB9A 457/4885SMN1; SMN2 1849/4885 |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | PPIP5K2, INPP5B, INPPL1 | ALDH1A1 4597/4885RAB9A 163/4885SMN1; SMN2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.